GlucoTrack, Inc. (GCTK) fell sharply on Thursday, dropping 25.26 percent, or $0.86, to trade at $2.54, despite the company announcing the issuance of three new U.S. patents covering its continuous blood glucose monitoring platform.
The medical device company said the patents strengthen its intellectual property around its fully implantable, multi-year continuous blood glucose monitoring system, including sensor chemistry, intravascular lead design, and low-power electronics, as it advances toward commercialization.
The stock opened at $3.38 after a previous close of $3.41 and traded in a wide range between $2.33 and $3.44 during the session on the Nasdaq. The bid was $2.73 and the ask $3.01.
Trading volume surged to about 13.38 million shares, far above the average volume of 84,247. GlucoTrack's 52-week range is $2.33 to $127.80.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.